新型非氟喹诺酮类药物奈莫沙星（TG-873870）与其他喹诺酮类药物对临床分离株的体外比较活性。
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
机构信息
Division of Infectious Diseases, National Health Research Institutes, 35 Keyan Rd. Zhunan, Taiwan 350.
出版信息
Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. doi: 10.1128/AAC.01197-09. Epub 2010 Jan 11.
Abstract
The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.
摘要
研究了新型非氟喹诺酮类药物奈莫沙星（TG-873870）对 770 株临床分离菌的体外抗菌活性。奈莫沙星（以马来酸盐形式 TG-875649 测试）对不同种的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌的体外活性优于环丙沙星和左氧氟沙星。TG-875649 的体外活性与莫西沙星相当，或优于包括对环丙沙星耐药、耐甲氧西林金黄色葡萄球菌和左氧氟沙星耐药肺炎链球菌在内的这些病原体。
相似文献
1
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.新型非氟喹诺酮类药物奈莫沙星（TG-873870）与其他喹诺酮类药物对临床分离株的体外比较活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. doi: 10.1128/AAC.01197-09. Epub 2010 Jan 11.
2
In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.在台湾，对具有不同耐药表型的金黄色葡萄球菌、肠球菌和肺炎链球菌的临床分离株进行体外药敏试验，评估新型非氟喹诺酮类药物奈莫沙星（TG-873870）的抗菌活性。
J Antimicrob Chemother. 2009 Dec;64(6):1226-9. doi: 10.1093/jac/dkp370. Epub 2009 Oct 14.
3
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.莫西沙星对环丙沙星敏感性降低的病原体的活性。
J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.
4
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.新型非氟喹诺酮药物奈莫沙星对 2440 株临床分离菌的体外抗菌活性研究
Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. doi: 10.1128/AAC.00078-09. Epub 2009 Sep 8.
5
Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.奈诺沙星对革兰氏阳性临床分离株具有强效活性，但对革兰氏阴性临床分离株无活性。
Clin Ter. 2015 Nov-Dec;166(6):e374-80. doi: 10.7417/T.2015.1903.
6
Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.台湾相关革兰氏阳性菌菌株中奈诺沙星和氟喹诺酮暴露导致的特定突变
Microb Drug Resist. 2020 Feb;26(2):110-117. doi: 10.1089/mdr.2019.0048. Epub 2019 Aug 30.
7
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.新型氟喹诺酮类药物ABT-492的体外抗菌效力及抗菌谱
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
8
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.1998-2007 年台湾幽门螺杆菌分离株对奈莫沙星、替加环素和其他抗菌药物的体外活性。
Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1369-75. doi: 10.1007/s10096-010-1009-9. Epub 2010 Jul 25.
9
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.DX-619及对照喹诺酮类药物对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.
10
In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.莫西沙星对医院分离株的体外抗菌活性：一项多中心研究。
Clin Microbiol Infect. 2003 Oct;9(10):997-1005. doi: 10.1046/j.1469-0691.2003.00696.x.
引用本文的文献
1
Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan.台湾地区当代耐甲氧西林金黄色葡萄球菌血流分离株中奈诺沙星与其他氟喹诺酮类药物的体外抗菌活性比较及其与耐药机制的相关性
Ann Clin Microbiol Antimicrob. 2025 Jan 17;24(1):5. doi: 10.1186/s12941-024-00772-6.
2
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.奈诺沙星在改善慢性阻塞性肺疾病急性加重患者的症状和延长下次加重时间方面优于莫西沙星。
Sci Rep. 2023 Oct 7;13(1):16954. doi: 10.1038/s41598-023-44188-2.
3
Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance.口服奈诺沙星的安全性：对临床试验和上市后监测的系统评价
Front Pharmacol. 2022 Dec 9;13:1067686. doi: 10.3389/fphar.2022.1067686. eCollection 2022.
4
Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an Dynamic Pharmacokinetic/Pharmacodynamic Model.奈诺沙星增强万古霉素对耐甲氧西林金黄色葡萄球菌的抗药性和抗耐药突变能力的动态药代动力学/药效学模型。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0180021. doi: 10.1128/AAC.01800-21. Epub 2021 Dec 13.
5
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.喹诺酮类的生物学效应：一类广谱抗菌药物。
Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153.
6
Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.千禧一代抗菌（氟）喹诺酮类药物的结构表征——塑造第五代产品
Pharmaceutics. 2021 Aug 18;13(8):1289. doi: 10.3390/pharmaceutics13081289.
7
Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against .奈诺沙星在中性粒细胞减少小鼠肺部感染模型中的药代动力学和药效学研究 针对…… （原文此处against后内容缺失）
Front Pharmacol. 2021 May 4;12:658558. doi: 10.3389/fphar.2021.658558. eCollection 2021.
8
Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia.奈诺沙星用于社区获得性肺炎门诊患者的疗效与安全性
Infect Drug Resist. 2020 Jul 2;13:2099-2104. doi: 10.2147/IDR.S248092. eCollection 2020.
9
Activities of Nemonoxacin and Other Antimicrobial Agents Against Human and Isolates and Their Defined Resistance Mechanisms.奈诺沙星及其他抗菌药物对人体及分离菌株的活性及其明确的耐药机制。
Front Microbiol. 2019 Aug 13;10:1890. doi: 10.3389/fmicb.2019.01890. eCollection 2019.
10
The Continuing Threat of Methicillin-Resistant .耐甲氧西林的持续威胁
Antibiotics (Basel). 2019 May 2;8(2):52. doi: 10.3390/antibiotics8020052.
本文引用的文献
1
Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.台湾产CTX-M型超广谱β-内酰胺酶的肺炎克雷伯菌分离株中氨基糖苷类耐药基因armA和rmtB的广泛传播。
Antimicrob Agents Chemother. 2009 Jan;53(1):104-11. doi: 10.1128/AAC.00852-08. Epub 2008 Oct 20.
2
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.肠杆菌科、假单胞菌属和不动杆菌属中的β-内酰胺酶威胁
Trends Microbiol. 2006 Sep;14(9):413-20. doi: 10.1016/j.tim.2006.07.008. Epub 2006 Jul 31.
3
Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan.台湾七个医学中心临床分离的大肠埃希菌和肺炎克雷伯菌中的超广谱β-内酰胺酶和质粒介导的AmpC酶
Antimicrob Agents Chemother. 2006 May;50(5):1861-4. doi: 10.1128/AAC.50.5.1861-1864.2006.
4
Antibacterial resistance worldwide: causes, challenges and responses.全球抗菌药物耐药性：原因、挑战及应对措施
Nat Med. 2004 Dec;10(12 Suppl):S122-9. doi: 10.1038/nm1145.
5
The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000.2000年台湾革兰氏阳性病原体的抗菌药物耐药性状况：台湾抗菌药物耐药性监测（TSAR）计划
Int J Antimicrob Agents. 2004 Apr;23(4):362-70. doi: 10.1016/j.ijantimicag.2003.09.021.
6
The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000.2000年台湾革兰氏阴性病原菌的抗菌药物耐药性状况：台湾抗菌药物耐药性监测（TSAR）项目
Diagn Microbiol Infect Dis. 2004 Mar;48(3):211-9. doi: 10.1016/j.diagmicrobio.2003.10.005.
Zotero 插件